Contribute Try STAT+ Today

WASHINGTON — The Biden administration has agreed to delay for a year the implementation of one of President Trump’s signature drug pricing policies.

The policy at issue would prevent drug makers and middlemen from negotiating rebates on prescription drugs. The prohibition was scheduled to go into effect in January 2022, but the Biden administration agreed to delay it until 2023, a court order filed Saturday showed. District Court Judge John Bates gave the Biden team until April 1 to decide whether it wants to continue defending the policy.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.